Corneal dendritic cells and the subbasal nerve plexus following neurotoxic treatment with oxaliplatin or paclitaxel

Jeremy Chung Bo Chiang1,2, David Goldstein2,3, Azadeh Tavakoli3, Terry Trinh3, Jacob Klisser3, Craig R. Lewis2,3, Michael Friedlander2,3, Thomas J. Naduvilath1,4, Kimberley Au3, Susanna B. Park5, Arun V. Krishnan3 & Maria Markoulli1

Immune cell infiltration has been implicated in neurotoxic chemotherapy for cancer treatment. However, our understanding of immune processes is still incomplete and current methods of observing immune cells are time consuming or invasive. Corneal dendritic cells are potent antigen-presenting cells and can be imaged with in-vivo corneal confocal microscopy. Corneal dendritic cell densities and nerve parameters in patients treated with neurotoxic chemotherapy were investigated. Patients treated for cancer with oxaliplatin (n = 39) or paclitaxel (n = 48), 3 to 24 months prior to assessment were recruited along with 40 healthy controls. Immature (ImDC), mature (MDC) and total dendritic cell densities (TotalDC), and corneal nerve parameters were analyzed from in-vivo corneal confocal microscopy images. ImDC was increased in the oxaliplatin group (Median, Md = 22.7 cells/mm²) compared to healthy controls (Md = 10.1 cells/mm², p = 0.001), but not in the paclitaxel group (Md = 10.6 cells/mm²). ImDC was also associated with higher oxaliplatin cumulative dose (r = 0.33, p = 0.04) and treatment cycles (r = 0.40, p = 0.01). There was no significant difference in MDC between the three groups (p > 0.05). Corneal nerve parameters were reduced in both oxaliplatin and paclitaxel groups compared to healthy controls (p < 0.05). There is evidence of elevation of corneal ImDC in oxaliplatin-treated patients. Further investigation is required to explore this potential link through longitudinal studies and animal or laboratory-based immunohistochemical research.
fibers and Langerhans cells from invasive skin biopsies. It is also less time consuming and has been increasingly used to observe neuroimmune features in the cornea including corneal dendritic cell density and behavior. Dendritic cells are the most potent antigen-presenting cells in the body and are the primary responders responsible for initiating inflammatory and immune responses to damage or toxicity. They are the main resident immune cells in the cornea, and can be differentiated morphologically into immature and mature cell types. Larger presence of immature dendritic cells is usually associated with an enhanced ability to mount an inflammatory response, whereas mature dendritic cells are derived from immature dendritic cells overexpressing costimulatory molecules such as CD80/CD86 and major histocompatibility complex (MHC) II to enhance their ability to active immunological processes. Unlike immature dendritic cells, mature cells suggest the presence of active inflammation.

Studies have shown an increase in the total number of corneal dendritic cells in other axonal degenerative conditions including diabetic peripheral neuropathy, and mature corneal dendritic cells have also been shown to be associated with increased systemic inflammatory signaling involving receptors of tumor necrosis factors (TNF). Notably, ocular surface changes such as immune cell infiltration or tear film inflammatory mediators often reflect the status of systemic inflammation. While evidence of corneal nerve fiber loss has been shown with neurotoxic chemotherapy in both human and animal models, the changes in resident dendritic cells with chemotherapy have been limited to isolated case reports and the potential changes in treated patients across different major drug types remain unknown. The current study is novel in its investigation of in-vivo corneal dendritic cell densities and corneal nerve parameters in patients treated with oxaliplatin or paclitaxel. The second aim was to correlate these corneal neuroimmune features with the severity of peripheral neuropathy.

Methods

Study design and patient selection. This cross-sectional study was approved by the South Eastern Sydney Health Service Human Research Ethics Committee. Participants provided written informed consent after explanation of the nature and possible consequences of the study in accordance with the tenets of the Declaration of Helsinki. All methods were conducted in accordance with relevant guidelines and regulations.

Eighty-seven patients who had completed neurotoxic chemotherapy 3 to 24 months prior to assessment (oxaliplatin, n = 39; paclitaxel, n = 48) were consecutively recruited by convenience sampling from the Department of Medical Oncology, Prince of Wales Hospital (Sydney, Australia). A group of age-matched healthy controls (n = 40) were recruited for comparison. Sample size was assessed based on power calculations undertaken using G’Power 3.1.9.4 (Heinrich Heine University, Dusseldorf, Germany). As there is currently no quantitative data in neurotoxic chemotherapy, this was based on the corneal dendritic cell density in diabetic participants (17.73 ± 1.45 cells/mm²) compared to controls (6.94 ± 1.58 cells/mm²). A minimum sample of 20 participants in each group was estimated to have 80% power to detect a minimum mean difference of 1.7 ± 1.6 cells/mm² at the 5% level of significance after accounting for Bonferroni corrected multiple comparisons.

Patients were excluded if they had a history of other medical conditions known to cause peripheral neuropathy including diabetes and chronic kidney disease, chronic demyelinating polyneuropathy, Sjögren’s syndrome and Charcot-Marie-Tooth disease. Medical records were also checked and the patients questioned during assessment for any such conditions including excessive alcohol consumption. Pregnant and lactating women, patients with a history of ocular trauma, ocular surgery or refractive surgery, active ocular conditions including iritis, corneal edema, herpetic ulcers, corneal dystrophies or glaucoma requiring treatment with intraocular pressure lowering eye drop medication were excluded. Those with significant corneal epitheliopathy indicated by grade > 2 fluorescein staining on the Efron scale, habitual soft and rigid contact lens wear, receiving corticosteroid eyedrops or systemic corticosteroid treatment, hormonal agents or oral retinoids at the time of assessment or those with known allergies to anesthetic eyedrops were also excluded.

Clinical ocular surface assessments. Visual acuity assessment and slit lamp biomicroscopy were conducted on all participants. Symptomatology of ocular surface dysfunction was assessed with the Ocular Surface Disease Index (OSDI), a validated 12-item questionnaire developed to assess the severity of dry eye disease in relation to three subcategories: severity of ocular symptoms, visual function and environmental triggers. The total score ranges from 0 to 100, with a total score > 12 indicating potential presence of dry eye disease. Corneal integrity and staining according to the Efron scale was assessed by instilling a fluorescein strip moistened with saline solution (sodium chloride 0.9%). Tear film breakup time (TBUT) was also determined by assessing the time between a blink and first signs of break in the fluorescein pattern. Corneal staining and TBUT were part of the dry eye assessment as markers of tear film homeostasis.

In-vivo corneal confocal microscopy. In-vivo corneal confocal microscopy was conducted according to previously published methods. Briefly, a laser scanning confocal microscope (Heidelberg Retina Tomograph III with Rostock Corneal module; Heidelberg Engineering GmbH, Heidelberg, Germany) was performed on participants after the cornea was anaesthetized with sterile 0.4% benoxinate hydrochloride. Five to eight images best representing the central cornea with less than 20% overlap between images, and three to five images of the inferior whorl region were identified. A validated automated image analysis software (ACCMetrics, The University of Manchester Intellectual Property UMIP, Manchester, United Kingdom) was used to analyze corneal nerve fiber length (CNFL, mm/mm²), corneal nerve fiber density (CNFD, no/mm²) and inferior whorl length (IWL, mm/mm²). The average nerve fiber length (ANFL = CNFL / 2) was also calculated.

Corneal dendritic cells identified in the corneal epithelium subbasal layer were defined as reflective bodies with dendritiform processes and were manually quantified by a masked, independent observer from the in-vivo...
corneal confocal microscopy images of the central cornea (Fig. 1). These were further classified into immature and mature dendritic cells. Immature dendritic cells (ImDC) were defined as small, reflective cell bodies with short discernible dendrites, tapered ends or processes (< 25 µm)\(^{16,19}\). These cells are able to undergo maturation to increase their potency in antigen processing and presentation leading to an inflammatory or immune response\(^{33}\). Mature dendritic cells (MDC) were defined as reflective, slender cell bodies often with multiple long dendritiform processes extending out from the main cell body (> 25 µm)\(^{16,19}\). These are usually regarded as markers of overt and active inflammation\(^{34}\). The total dendritic cell densities including ImDC and MDC (TotalDC) were also noted.

**Peripheral neurotoxicity assessments.** Assessment of peripheral nerve health have been described previously\(^{22}\). Neuropathy status in all participants was graded using the reduced version of the Total Neuropathy Scale (TNSr©Johns Hopkins University) which assesses clinical parameters across 8 domains (sensory symptoms, weakness symptoms, pin prick sensibility, vibration threshold, strength, deep tendon reflexes, sensory nerve, and motor nerve conduction studies) with grades ranging from 0 to 4 where 0 signifies no deficit and 4 represents severe changes\(^{35,36}\). The total score ranges from 0 to 32. Nerve conduction studies were undertaken in the sural sensory and tibial motor nerves as per standard protocols\(^{37}\). Clinical assessment was also conducted using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3 sensory subscale for sensory peripheral neuropathy\(^{38}\). The European Organization for Research and Treatment of Cancer Quality of Life—Chemotherapy induced Peripheral Neuropathy questionnaire (EORTC QLQ-CIPN20) is a 20-item validated questionnaire and was used as a patient reported outcome assessing peripheral neuropathy symptomatology and potential impact on functional activities of daily living\(^{39}\). Each participant indicated the degree to which they have experienced each item by rating it from 1 to 4, where 1 signifies ‘not at all’.
all’ and 4 represents ‘very much’. The total scores were then linearly converted to a 0–100 scale, with higher scores indicating higher symptom burden.

Statistical analysis. Statistical analysis was conducted using SPSS (version 25.0, IBM Corp., Armonk; NY, USA). As a preliminary assessment of the reproducibility of dendritic cell density measures, the intraclass correlation coefficient (ICC) based on absolute agreement (two-way random effects, average measures) was 0.994 (95% confidence interval (CI) 0.988–0.996) for immature dendritic cells, and 0.988 (95% CI 0.980–0.993) for mature dendritic cells between two masked observers (JK, AT). ICC based on absolute agreement for intra-reliability (two-way mixed effects, single measures) was 0.984 (95% CI 0.947–0.994) for ImDC, and 0.966 (95% CI 0.917–0.987) for MDC.

Normality was assessed with Shapiro–Wilk test and Q-Q plots. Preliminary data checks of dendritic cell densities indicated that there was large variability relative to the mean, with the distribution being skewed to the right. Hence a logarithmic transformation was applied to the raw dendritic cell density data. Univariate analysis using one-way ANOVA for parametric data (age and body mass index, BMI) and Kruskal Wallis test for non-parametric data (clinical ocular and peripheral neuropathy measures) with post-hoc Bonferroni adjustment of p-values was used to compare measures between the three groups. The proportion of participants in each group with dry eye disease (OSDI > 12 with presence of corneal staining, with grade ≥ 1 on the Efron scale or TBUT < 10 s) was also determined. Chi squared test of independence was used for comparing gender proportions and the prevalence rates of dry eye disease between participants.

A general linear model was conducted to assess if dendritic cell densities, differences between patients were further stratified according to higher and lower neuropathy severity groups based on the median of the TSNr scores (≤ Median TSNr: lower neuropathy severity; > Median TSNr: higher neuropathy severity) were investigated with independent t-test (age and BMI), Chi-squared test of independence (gender and dry eye proportions) or Mann–Whitney U test (clinical ocular and peripheral neuropathy measures). A general linear model was also used to assess the differences in dendritic cell densities and corneal nerve parameters in patients according to higher and lower neuropathy severity while accounting for confounding factors as described before. Post hoc pairwise comparisons between groups were adjusted using Bonferroni correction. Two-tailed level of significance was set at p < 0.05.

Results
Clinical and demographic data. The clinical and demographic data for patients treated with oxaliplatin and paclitaxel are presented in Table 1. Peripheral neuropathy measures including TSNr scores, sural and tibial nerve amplitudes, NCI-CTCAE and EORTC QLQ-CIPN20 scores are also presented in Table 1. There were no significant differences in age between the three groups (p = 0.50). The paclitaxel group had higher BMI than healthy controls (p = 0.02). There were more females in the paclitaxel group compared to the oxaliplatin group (p = 0.02). The prevalence of dry eye disease in the paclitaxel was 13/48 (27%) compared to 2/39 (5%) in the paclitaxel group had worse OSDI scores compared with the oxaliplatin group (p = 0.008) and healthy controls.

Clinical and demographic data indicated that there was large variability relative to the mean, with the distribution being skewed to the right. A logarithmic transformation was applied to the raw dendritic cell density data. Univariate analysis using one-way ANOVA for parametric data (age and BMI) and Kruskal Wallis test for non-parametric data (clinical ocular and peripheral neuropathy measures) with post-hoc Bonferroni adjustment of p-values was used to compare measures between the three groups. The proportion of participants in each group with dry eye disease (OSDI > 12 with presence of corneal staining, with grade ≥ 1 on the Efron scale or TBUT < 10 s) was also determined. Chi-squared test of independence was used for comparing gender proportions and the prevalence rates of dry eye disease between participants.

A general linear model was conducted to assess if dendritic cell densities, differences between patients were further stratified according to higher and lower neuropathy severity groups based on the median of the TSNr scores (≤ Median TSNr: lower neuropathy severity; > Median TSNr: higher neuropathy severity) were investigated with independent t-test (age and BMI), Chi-squared test of independence (gender and dry eye proportions) or Mann–Whitney U test (clinical ocular and peripheral neuropathy measures). A general linear model was also used to assess the differences in dendritic cell densities and corneal nerve parameters in patients according to higher and lower neuropathy severity while accounting for confounding factors as described before. Post hoc pairwise comparisons between groups were adjusted using Bonferroni correction. Two-tailed level of significance was set at p < 0.05.

Dendritic cell densities and corneal nerves with oxaliplatin and paclitaxel treatment. Representative images of the corneal nerves and dendritic cells for the oxaliplatin, paclitaxel and healthy control groups are shown in Fig. 1. Table 2 shows the model based estimates for dendritic cell densities and corneal nerve parameters for the three groups following adjustment for age, gender, BMI and dry eye diagnosis. Figure 2 shows the distribution of dendritic cell densities for each group.

Based on the general linear model, ImDC was significantly higher in the oxaliplatin group (Median [Inter-quartile range]: 22.7 cells/mm² [11.7–40.6]) compared to healthy controls (10.1 cells/mm² [3.5–17.6], p = 0.03). However, there was no significant difference in ImDC between healthy controls and the paclitaxel group (10.6 cells/mm² [3.3–24.0], p = 0.99). A similar increase in TotalDC (28.1 cells/mm² [17.2–46.9]) was observed in the oxaliplatin group compared to healthy controls (12.2 cells/mm² [4.7–27.9], p = 0.02). There were no significant differences in ImDC and TotalDC between the oxaliplatin group and the paclitaxel group (ImDC: 10.6 cells/mm² [3.3–24.0], p = 0.32; TotalDC: 14.8 cells/mm² [5.7–28.1], p = 0.36). MDC was not significantly different between the three groups (p > 0.05; Table 2).
Table 1. Demographic, ocular surface measures, corneal nerve and neuropathy measures of patients who received oxaliplatin or paclitaxel for cancer treatment. Data is presented as mean ± standard deviation or median [interquartile range Q1–Q3]. Compared with healthy controls: †p = 0.02; ‡p < 0.001; §p = 0.002; **p = 0.001; ***p = 0.007; ****p = 0.003; *****p = 0.006. Compared with oxaliplatin group: ¶p < 0.001; *p = 0.008.

| Characteristics | Participants | Oxaliplatin (n = 39) | Paclitaxel (n = 48) | Healthy controls (n = 40) |
|-----------------|--------------|----------------------|---------------------|--------------------------|
| **Age**         |              | 60.8 ± 9.5           | 58.6 ± 10.4         | 58.9 ± 7.9               |
| BMI, kg/m²      |              | 27.0 ± 5.0           | 27.4 ± 5.4²         | 24.4 ± 4.1               |
| Gender (female) |              | 18 (46%)             | 46 (96%)⁴          | 23 (58%)                 |
| **Primary cancer site** |          |                      |                     |                          |
| Colorectal      |              | 32 (82%)             | 0 (0%)              | N/A                      |
| Pancreatic      |              | 4 (10%)              | 0 (0%)              | N/A                      |
| Other gastrointestinal |    | 3 (8%)              | 0 (0%)              | N/A                      |
| Breast          |              | 0 (0%)               | 41 (85%)            | N/A                      |
| Gynecological   |              | 0 (0%)               | 7 (15%)             | N/A                      |
| **UICC staging prior to treatment** |          |                      |                     |                          |
| I               |              | 1 (3%)               | 10 (21%)            | N/A                      |
| II              |              | 6 (15%)              | 16 (33%)            | N/A                      |
| III             |              | 17 (44%)             | 15 (31%)            | N/A                      |
| IV              |              | 12 (31%)             | 0 (0%)              | N/A                      |
| Unspecified     |              | 3 (8%)               | 7 (15%)             | N/A                      |
| **Number of treatment cycles** |          | 8 [5.8–10.3]         | 10.5 [7–12]         | N/A                      |
| **Mean cumulative dose, mg/m²** |          | 663.78 ± 230.30      | 852.21 ± 165.28     | N/A                      |
| **Period post-treatment, months** |          | 10.3 ± 7.3           | 15.3 ± 7.3          | N/A                      |
| **NCI-CTCAE for peripheral sensory neuropathy (range: 0–4)** |          | 2 [1, 2]             | 1 [1, 2]             | N/A                      |
| **EORTC QLQ-CIPN20 (range: 0–100)** |          | 19.3 [12.3–31.6]     | 15.8 [5.7–29.4]     | N/A                      |
| **TNSr scores (range: 0–32)** |          | 5 [3–11]¹           | 3.5 [1–7]¹          | 0 [0–1]                  |
| **Sural nerve amplitude, µV** |          | 6.6 [3.3–11.7]¹      | 12.8 [9.0–17.0]¹    | 18.5 [9.3–26.3]          |
| **Tibial nerve amplitude, mV** |          | 9.8 [3.9–14.1]       | 12.6 [7.2–16.6]     | 12.5 [8.9–14.8]          |
| logVA           |              | 0.14 [0.10–0.30]     | 0.14 [0.02–0.22]    | 0.10 [0–0.18]            |
| **OSDI**        |              | 11 [6.8–13]         | 10 [7–12]          | 12 [10–12.5]            |
| **TBUT**        |              | 0 [0–0]              | 0 [0–1]            | 0 [0–2]                 |
| **Corneal staining** |        | 0 [0–0]              | 0 [0–0]            | 0 [0–0]                |

Table 2. Model based estimates from general linear model after adjusting for age, body mass index, gender and dry eye diagnosis for dendritic cell densities and corneal nerve parameters in participants. Data is presented as mean from model based estimates and log mean value in parentheses, with 95% confidence intervals (CI). Compared with healthy controls: †p = 0.02; ²p < 0.001; ³p = 0.002; ⁴p = 0.001; ⁵p = 0.007; ⁶p = 0.003; ⁷p = 0.006. Compared with oxaliplatin group: ⁸p < 0.001; ⁹p = 0.008. BMI body mass index, NCI-CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events, EORTC QLQ-CIPN20 the European Organization for Research and Treatment of Cancer Quality of Life—Chemotherapy-induced Peripheral Neuropathy questionnaire, TNSr reduced version of Total Neuropathy Scale, logVA log visual acuities, OSDI Ocular Surface Discomfort Index, TBUT tear film break up time, CNFD corneal nerve fiber density, CNFL corneal nerve fiber length, IWL inferior whorl length, ANFL average nerve fiber length.

| Parameters     | Participants | Oxaliplatin (n = 39) | Paclitaxel (n = 48) | Healthy controls (n = 40) |
|----------------|--------------|----------------------|---------------------|--------------------------|
| **ImDC, cells/mm²** |              | 18.2 (1.28)³         | 10.9 to 30.1        | 11.2 (1.09)              |
| **MDC, cells/mm²** |              | 3.9 (0.69)           | 2.2 to 6.6          | 2.7 (0.57)               |
| **TotalDC, cells/mm²** |          | 24.2 (1.40)²        | 15.0 to 38.8        | 15.8 (1.23)              |
| **CNFD, no/mm²** |              | 15.4 *             | 12.0 to 14.7        | 13.3 **                   |
| **CNFL, mm²/mm²** |              | 12.2 **           | 10.6 to 13.9        | 13.3                      |
| **IWL, mm²/mm²** |              | 12.9 ***           | 11.5 to 14.2        | 13.3 ***                  |
| **ANFL, mm²/mm²** |              | 12.9 **           | 11.5 to 14.2        | 13.3 **                   |
Both CNFD and CNFL were reduced in the oxaliplatin (CNFD: 23.2 ± 6.3 no/mm², p = 0.01; CNFL: 13.7 ± 2.9 mm/mm², p = 0.004) and paclitaxel groups (CNFD: 21.7 ± 7.6 mm/mm², p = 0.005; CNFL: 13.1 ± 3.8 mm/mm², p = 0.006) compared to healthy controls (CNFD: 28.0 ± 6.4 no/mm²; CNFL: 16.3 ± 3.2 mm/mm²). IWL and ANFL were similarly reduced in the oxaliplatin group (IWL: 12.5 ± 3.7 mm/mm², p = 0.001; ANFL: 12.5 ± 3.7 mm/mm², p = 0.001) compared to healthy controls (IWL: 16.3 ± 3.9 mm/mm²; ANFL: 16.3 ± 3.1 mm/mm²). ANFL was also reduced in the paclitaxel group (13.4 ± 3.8 mm/mm², p = 0.008) compared to healthy controls. There were no significant differences in corneal nerve parameter between the oxaliplatin and paclitaxel groups (p > 0.05; Table 2).

Correlation analysis showed that higher MDC was associated with CNFD loss in the oxaliplatin group (r = 0.34, p = 0.038; Fig. 3a, Table 3). Higher MDC were also associated with loss of CNFD and IWL in paclitaxel
Corneal neuroimmune features in peripheral neuropathy. The oxaliplatin group, which was the only treated group that showed a significant increase in ImDC and TotalDC compared to healthy controls, were stratified according to lower neuropathy severity group (TNSr ≤ 5) and higher neuropathy severity (TNSr > 5) with healthy controls. Data is presented as mean ± standard deviation or median [interquartile range Q1–Q3]. For the dendritic cell densities and corneal nerve parameters, data is presented as mean from model based estimates with 95% confidence intervals (CI). The log mean values for dendritic cell densities are presented in parentheses. 

Table 3. Associations between dendritic cell densities and corneal nerve parameters for patients treated with oxaliplatin or paclitaxel. Data is reported as r (p-value) with statistically significant correlations highlighted in bold. ImDC immature dendritic cell density, MDC mature dendritic cell density, TotalDC total dendritic cell density, CNFD corneal nerve fiber density, CNFL corneal nerve fiber length, IWL inferior whorl length, ANFL average nerve fiber length.

Table 4. Model based estimates from general linear model for corneal neuroimmune features in oxaliplatin-treated patients post-cessation stratified according to lower (reduced version total neuropathy scale (TNSr) ≤ 5) and higher neuropathy severity (TNSr > 5) with healthy controls. Data is presented as mean ± standard deviation or median [interquartile range Q1–Q3]. For the dendritic cell densities and corneal nerve parameters, data is presented as mean from model based estimates with 95% confidence intervals (CI). The log mean values for dendritic cell densities are presented in parentheses.

(r = 0.35, p = 0.02 and r = 0.32, p = 0.03; Fig. 3b,c; Table 3). Conversely, there was an association between higher MDC with higher CNFD (r = 0.32, p = 0.048) and higher CNFL (r = 0.34, p = 0.04) in healthy controls. Higher number of treatment cycles in the oxaliplatin group was associated with the increase in ImDC (r = 0.33, p = 0.04; Fig. 3d) and TotalDC (r = 0.37, p = 0.02) observed in the oxaliplatin group (Supplementary Table S2). Similarly, higher cumulative dose of oxaliplatin was associated with elevated ImDC (r = 0.40, p = 0.01; Fig. 3e) and TotalDC (r = 0.42, p = 0.009). There were no associations between dendritic cell densities with treatment data or neuropathy severity in the paclitaxel group (Supplementary Table S2 and Supplementary Table S3). Additionally, no associations were found between corneal nerve parameters with treatment data or neuropathy severity in the oxaliplatin or paclitaxel groups (Supplementary Table S2 and Supplementary Table S3).
Discussion

Our study investigated corneal neuroimmune features observed with in-vivo corneal confocal microscopy in patients who have completed treatment with neurotoxic chemotherapy with either paclitaxel or oxaliplatin. A major focus was to assess the potential effect of neurotoxic chemotherapy on corneal dendritic cells which are pertinent resident immune cells. A significant increase in ImDC in the oxaliplatin group was observed well after treatment cessation, even after accounting for age, gender, BMI and presence of dry eye disease. However, this was not associated with neuropathy severity. Conversely, there was no elevation in density observed in paclitaxel-treated patients. Dry eye disease, which has been associated with inflammatory changes on the ocular surface causing symptoms of discomfort and surface damage, is unlikely to contribute to the differences as there was no evidence of significant ocular surface dysfunction in the oxaliplatin group. This further suggests that the increase in ImDC in the oxaliplatin group is indicative of low-level inflammatory presence, rather than an active clinical or pathological manifestation such as that seen in severe keratitis or keratopathies, which would have been indicated by significant increases in MDC. ImDC elevation is associated with an enhanced ability to phagocytose antigens and mount an inflammatory response and hence may indicate a sustained, chronic low-level inflammation in oxaliplatin-treated patients as opposed to an active overt inflammation.

In the current study, the increase in ImDC in the oxaliplatin group was associated with prolonged prior exposure to oxaliplatin indicated by the number of treatment cycles and cumulative dose of oxaliplatin. Oxaliplatin has been shown to increase inflammatory mediators including tumor necrosis factor alpha (TNF-α) and interleukin 1 beta (IL-1β), and immune cells such as dendritic cells and enhanced cytotoxic T cells elsewhere in lung carcinoma tissues of murine models. While systemic inflammatory mediators of treated patients were not investigated in the current study, a previous study of oxaliplatin-treated patients has shown an increase in pro-inflammatory mediators including the transcriptional factor nuclear factor-kappa light chain enhancer of B cells (NF-κB) measured immediately after treatment cessation. These findings may be of clinical importance in developing more targeted anti-inflammatory or immunosuppressive approaches while minimizing adverse reactions associated with traditional steroidal agents. Whether these elevated levels are sustained chronically post-treatment is yet to be investigated. However, platinum compounds including oxaliplatin and cisplatin can persist within the body including the skin and blood years after completion of treatment, suggesting that post-treatment is yet to be investigated. However, platinum compounds including oxaliplatin and cisplatin can persist within the body including the skin and blood years after completion of treatment, indicating a sustained, chronic but subclinical impact on potent antigen-presenting cells.

The current study also showed no significant changes in dendritic cells in paclitaxel-treated participants. Although paclitaxel also increases inflammatory cytokines including IL-1β and IL-6 in the dorsal root ganglia, it has been shown to have little impact on antigen presentation capabilities of dendritic cells, inducing a reduction in dendritic cell size and loss of dendritic processes. In contrast, oxaliplatin seems to have a more stimulatory impact on dendritic cells, which may explain the increase in densities in oxaliplatin-treated patients but not in paclitaxel-treated patients. We also identified higher prevalence of dry eye disease in the paclitaxel group compared to the oxaliplatin group and healthy controls. This may be due to the greater proportion of females in the paclitaxel group as female gender has been associated with higher risk of dry eye disease, although other unexplored factors may play a role. Dry eye disease is an ocular surface condition where cellular disruption occurs due to the loss of homeostasis regulating tear film quality and ocular surface health which leads to symptomatic burden. Further research is required to investigate whether paclitaxel could additionally disrupt ocular surface homeostasis through corneal nerve dysfunction or neuropeptide dysregulation such as expression of substance P involved in inflammatory processes as has been shown previously, thus contributing to dry eye disease.

The association between MDC and corneal nerve loss in the drug groups observed in the current study may reflect a neuroimmune interaction between these immune cells and corneal nerves as reflected by other studies in both human and animal models. Conversely, in healthy individuals, higher MDC seems to be associated with larger corneal nerve parameters particularly higher CNFD and CNFL in our study. This positive association between has been observed previously; whereby dendritic cells support corneal nerve growth and maintenance in healthy humans and animals. This may occur through expression of neurotrophic factors such as ciliary neurotrophic factors (CNTF) in the healthy state. However, higher MDC in pathological conditions such as diabetes or exposure to toxins may be linked with corneal nerve loss and dysfunction through prolonged adverse pro-inflammatory effects. This supports a potential differential role of MDC in regulating corneal nerve morphology depending upon the degree of activation of the immune system and the state of disease or health.

Our study did not find an association between severity of the neuropathy in either drug group and dendritic cell densities, which may reflect the complex interplay of more pertinent factors which could potentially contribute to persistent chronic neuropathy including downstream inflammatory processes involving cytokine and chemokine action and genetic polymorphisms. In addition, there remains a lack of research on systemic inflammation in cancer survivors and its effect on dendritic cell populations. The current study is further limited by its cross-sectional nature, and longitudinal studies are required to measure corneal neuroimmune changes in patients during and after treatment. Any potential longstanding impact of the cancer itself on corneal nerves, dendritic cells and peripheral nerves which was not assessed in the current study should also be further investigated. However, paraneoplastic syndromes are usually subacute or fulminant and subside after anticancer treatment. Ferdousi et al. showed a reduction in corneal nerves in patients with gastrointestinal cancer before treatment, and a subsequent increase with three cycles of platinum-compound treatment thought to be due to nerve regeneration. Larger studies with longer follow up periods are required to confirm such observations including the relative impact of neurotoxic drugs on corneal nerves. Laboratory-based immunohistochemical
studies would also be important to further understand corneal dendritic cell function and behavior in response to oxaliplatin and paclitaxel. Markers of systemic inflammation were not investigated in the current study which focused on the observation of potential corneal dendritic cell changes with in-vivo corneal confocal microscopy. Further studies to better understand the potential link between systemic and local ocular inflammatory markers in neurotoxicity are required.

The current study revealed an elevation of corneal ImDC in patients who have received oxaliplatin treatment, but not paclitaxel, although this was not associated with peripheral neuropathy severity. Further investigation is required to explore this potential link through longitudinal studies and animal or laboratory-based immunohistochemical research. Importantly, loss of corneal nerves was also prominent in treated patients. Future studies should explore these corneal neural and inflammatory changes detectable in an in-vivo, non-invasive manner during neurotoxic chemotherapy treatment from baseline.

Data availability

The datasets generated and analyzed during the study are available from the corresponding author on request.

Received: 28 September 2021; Accepted: 8 November 2021

Published online: 24 November 2021

References

1. Park, S. B. et al. Chemotherapy-induced peripheral neurotoxicity: A critical analysis. CA Cancer J. Clin. 63, 419–437. https://doi.org/10.3322/caac.21204 (2013).
2. Sertemy, M. et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain 155, 2461–2470. https://doi.org/10.1016/j.pain.2014.09.020 (2014).
3. Brady, B. L. et al. Chemotherapy-induced peripheral neuropathy in metastatic breast cancer patients initiating intravenous paclitaxel/nab-paclitaxel. Am. J. Manag. Care. https://doi.org/10.7776/ajmc.2021.88562 (2020).
4. Bonhof, C. S. et al. The course of peripheral neuropathy and its association with health-related quality of life among colorectal cancer patients. J. Cancer Surviv. 15, 190–200. https://doi.org/10.1007/s11764-020-00923-6 (2021).
5. Makker, P. G. S. et al. Characterisation of immune and neuroinflammatory changes associated with chemotherapy-induced peripheral neuropathy. PLoS ONE 12, e0170814–e0170814. https://doi.org/10.1371/journal.pone.0170814 (2017).
6. Luo, H. et al. Interleukin-17 regulates neuron-glial communications, synaptic transmission, and neuropathic pain after chemotherapy. Cell Rep. 29, 2384-2397.e2385. https://doi.org/10.1016/j.celrep.2019.10.083 (2019).
7. Zhang, H. et al. Dorsal root ganglion infiltration by macrophages contributes to paclitaxel chemotherapy-induced peripheral neuropathy. J. Pain 17, 775–786. https://doi.org/10.1016/j.jpain.2016.02.011 (2016).
8. Liu, X. J. et al. Nociceptive neurons regulate innate and adaptive immunity and neuropathic pain through MyD88 adapter. Cell Rep. 24, 1374–1377. https://doi.org/10.1016/j.celrep.2014.10.006 (2016).
9. Kim, D., You, B., Lim, H. & Lee, S. J. Toll-like receptor 2 contributes to chemokine gene expression and macrophage infiltration in the dorsal root ganglia after peripheral nerve injury. Mol. Pain 7, 74. https://doi.org/10.1186/1744-8069-7-74 (2011).
10. Lees, J. G. et al. Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy. Eur. J. Cancer 73, 22–29. https://doi.org/10.1016/j.ejca.2016.12.006 (2017).

11. Patel, S., Hwang, J., Mehra, D. & Galor, A. Corneal nerve abnormalities in ocular and systemic diseases. Exp. Eye Res. 202, 108284. https://doi.org/10.1016/j.exer.2020.108284 (2021).
12. Petropoulos, I. N. et al. Corneal confocal microscopy: Ready for prime time. Clin. Exp. Optom. 103, 265–277. https://doi.org/10.1111/cxo.12887 (2020).
13. Anand, P. et al. Rational treatment of chemotherapy-induced peripheral neuropathy with capsaicin 8% patch: From pain relief towards disease modification. J. Pain Res. 12, 2039–2052. https://doi.org/10.2147/jpr.s221392 (2019).
14. Colorado, L. H., Markoulli, M. & Edwards, K. The relationship between corneal dendritic cells, corneal nerve morphology and tear inflammatory mediators and neuropeptides in healthy individuals. Curr. Eye Res. 44, 840–848. https://doi.org/10.1080/02713683.2019.1600196 (2019).
15. Colorado, L. H., Edwards, K., Chinnery, H. R. & Bazan, H. E. In vivo immune cell dynamics in the human cornea. Exp. Eye Res. 199, 108168. https://doi.org/10.1016/j.exer.2020.108168 (2020).
16. Mastropasqua, L. et al. Epithelial dendritic cell distribution in normal and inflamed human cornea: In vivo confocal microscopy study. Am. J. Ophthalmol. 142, 736–744. https://doi.org/10.1016/j.ajo.2006.06.057 (2006).
17. Galletti, J. G. & de Paiva, C. S. The ocular surface immune system through the eyes of aging. Ocul. Surf. 20, 139–162. https://doi.org/10.1016/j.jos.2021.02.007 (2021).
18. Hamrah, P., Huq, S. O., Liu, Y., Zhang, Q. & Dana, M. R. Corneal immunity is mediated by heterogeneous population of antigen-presenting cells. J. Leukoc. Biol. 79, 172–179. https://doi.org/10.1189/jlb.1102544 (2003).
19. Lagali, N. S. et al. Dendritic cell maturation in the corneal epithelium with onset of type 2 diabetes is associated with tumor necrosis factor receptor superfamily member 9. Sci. Rep. 8, 14248 (2018).
20. Tavakoli, M., Boulton, A. J. M., Efron, N. & Malik, R. A. Increased Langerhan cell density and corneal nerve damage in diabetic patients: Role of immune mechanisms in human diabetic neuropathy. Cont. Lens Anterior Eye 34, 7–11 (2011).
21. Shah, R. et al. Systemic diseases and the cornea. Exp. Eye Res. 204, 108455. https://doi.org/10.1016/j.exer.2021.108455 (2021).
22. Chiang, J. C. B. et al. A cross-sectional study of sub-basal corneal nerve reduction following neurotoxic chemotherapy. Transl. Vis. Sci. Technol. 10, 24–24. https://doi.org/10.1167/tvst.10.1.24 (2021).
23. Ferrari, G., Nalassamy, N., Downs, H., Dana, R. & Oaklander, A. L. Corneal innervation as a window to peripheral neuropathies. Exp. Eye Res. 113, 148–150 (2013).
24. Sterenczak, K. A. et al. Burst of corneal dendritic cells during trastuzumab and paclitaxel treatment. Diagnostics 11, 838. https://doi.org/10.3390/diagnostics11050838 (2021).
25. National Health and Medical Research Council, Australian Research Council & Universities Australia. Australian Guidelines to Reduce Health Risks from Drinking Alcohol. (Commonwealth of Australia, 2020).
26. Efron, N., Morgan, P. B. & Katarsa, S. S. Validation of grading scales for contact lens complications. Ophthalmic Physiol. Opt. 21, 17–29 (2001).
27. Schuffner, R. M., Christianson, M. D., Jacobsen, G., Hirsch, J. D. & Reis, B. L. Reliability and validity of the ocular surface disease index. Arch. Ophthalmol. 118, 615–621. https://doi.org/10.1001/archophthalmol.118.5.615 (2000).
28. Miller, K. L. et al. Minimal clinically important difference for the ocular surface disease index. Arch. Ophthalmol. 128, 94–101. https://doi.org/10.1001/archophthalmol.2009.356 (2010).
30. Vagenas, D.
31. Chen, X.
32. Dabbah, M. A., Graham, J., Petropoulos, I. N., Tavakoli, M. & Malik, R. A. Automatic analysis of diabetic peripheral neuropathy
33. Jamali, A.
40. Bron, A. J.
44. Fumagalli, G., Monza, L., Cavaletti, G., Rigolio, R. & Meregalli, C. Neuroinflammatory process involved in different preclinical
45. Sun, F.
49. Sprauten, M.
54. Sullivan, D. A.
60. Gao, N., Yan, C., Lee, P., Sun, H. & Yu, F. S. Dendritic cell dysfunction and diabetic sensory neuropathy in the cornea.
59. Gao, N., Lee, P. & Yu, F. S. Intraepithelial dendritic cells and sensory nerves are structurally associated and functional interdepend-
58. Rincon-Frutos, L.
53. Hong, X.
57. Guzmán, M.
1097/ OPX. 0b013 e3182 4ee8c9 (2012).
52–57. https://doi.org/10.1167/ iovs. 10- 5598 (2011).
285–290. https://doi.org/10.11186/1741-2172-11-14 (2010).
267–276. https://doi.org/10.3389/fimmu. 2020. 626687.
251–259. https://doi.org/10.1016/j. yexcr. 2017. 12. 018 (2018).
226–235 (2011).
251–259. https://doi.org/10.1016/j. jtos. 2017. 05. 011 (2017).
115–139. https://doi.org/10.1097/00009072-0000467-336 (2010).
1803–1810 (2012).
135–141. https://doi.org/10.1111/j. 1085- 9489. 2006. 00078.x (2006).
101–111 (2019).
25–31. https://doi.org/10.1016/j. jtos. 2017.15. 438–510. https://doi.org/10.1016/j. ejca. 2005. 02. 012 (2005).
1013–1017. https://doi.org/10.1016/j. eyrol. 2010. 02. 028 (2010).
1012–1017. https://doi.org/10.1007/ s12253- 013- 9691-4 (2014).
126, 1998–2011 (2016).
1325–1350. https://doi.org/10.1097/ RX.0b013e31832ed6c1 (2011).
1013–1017. https://doi.org/10.1016/j. eyrol. 2010. 02. 028 (2010).
1012–1017. https://doi.org/10.1007/ s12253- 013- 9691-4 (2014).
126, 1998–2011 (2016).
1325–1350. https://doi.org/10.1097/ RX.0b013e31832ed6c1 (2011).
1013–1017. https://doi.org/10.1016/j. eyrol. 2010. 02. 028 (2010).
1012–1017. https://doi.org/10.1007/ s12253- 013- 9691-4 (2014).
126, 1998–2011 (2016).
1325–1350. https://doi.org/10.1097/ RX.0b013e31832ed6c1 (2011).
1013–1017. https://doi.org/10.1016/j. eyrol. 2010. 02. 028 (2010).
1012–1017. https://doi.org/10.1007/ s12253- 013- 9691-4 (2014).
126, 1998–2011 (2016).
1325–1350. https://doi.org/10.1097/ RX.0b013e31832ed6c1 (2011).
1013–1017. https://doi.org/10.1016/j. eyrol. 2010. 02. 028 (2010).
1012–1017. https://doi.org/10.1007/ s12253- 013- 9691-4 (2014).
126, 1998–2011 (2016).
1325–1350. https://doi.org/10.1097/ RX.0b013e31832ed6c1 (2011).
1013–1017. https://doi.org/10.1016/j. eyrol. 2010. 02. 028 (2010).
1012–1017. https://doi.org/10.1007/ s12253- 013- 9691-4 (2014).
126, 1998–2011 (2016).
1325–1350. https://doi.org/10.1097/ RX.0b013e31832ed6c1 (2011).
1013–1017. https://doi.org/10.1016/j. eyrol. 2010. 02. 028 (2010).
1012–1017. https://doi.org/10.1007/ s12253- 013- 9691-4 (2014).
126, 1998–2011 (2016).
1325–1350. https://doi.org/10.1097/ RX.0b013e31832ed6c1 (2011).
1013–1017. https://doi.org/10.1016/j. eyrol. 2010. 02. 028 (2010).
1012–1017. https://doi.org/10.1007/ s12253- 013- 9691-4 (2014).
68. Ferdousi, M. et al. Corneal confocal microscopy detects small fibre neuropathy in patients with upper gastrointestinal cancer and nerve regeneration in chemotherapy induced peripheral neuropathy. PLoS ONE 10, e0139394–e0139394. https://doi.org/10.1371/journal.pone.0139394 (2015).

Acknowledgements
The authors would like to thank Prince of Wales Hospital staff and medical oncologists for their assistance in patient recruitment.

Author contributions
J.C.B.C., D.G., A.V.K. and M.M. designed the study. J.C.B.C., T.T. and K.A. recruited patients aided by D.G., M.F. and C.R.L. J.C.B.C, T.T., and K.A. conducted data acquisition. J.C.B.C., T.J.N., A.T. and J.K. conducted the data and statistical analysis. D.G., S.B.P., A.V.K. and M.M. supervised the study. J.C.B.C. conducted the draft preparation. All authors reviewed the manuscript.

Funding
This work was supported by an Australian Government Research Training Program (RTP) Scholarship awarded by UNSW Sydney to J.C.B.C. This study was supported by a Cancer Institute NSW Program Grant (14/TPG/1-05) and a National Health and Medical Research Council of Australia (NHMRC) Project Grant (1080521). S.B.P. is supported by an NHMRC Career Development Fellowship (1148595).

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-02439-0.

Correspondence and requests for materials should be addressed to J.C.B.C.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021